The SECAR study: Sodium selenite reverses chemotherapy resistance

- After a monotherapy with high-dose sodium selenite, therapy-resistant tumors once again respond to chemotherapy
- High-dose sodium selenite stabilizes more than a third of the patients with therapy-resistant, advanced tumors
Therapy-resistant tumors respond again to chemotherapy after monotherapy with high-dose sodium selenite

Meanwhile, high-dose sodium selenite has established itself in cancer therapy as an additive and adjunctive medication (e.g. selenase®). Nevertheless, questions still remain concerning the toxicity of dosages from 1,000 to 2,000 µg per day.

The SECAR study conducted by the renowned Karolinska Institute in Sweden could rebut these misgivings in a dose-escalating clinical trial with sodium selenite using dosages of up to 18,500 µg selenium as sodium selenite. [1]

Moreover, this study pursued a new approach to the use of sodium selenite for cancer patients. Very high-dose sodium selenite was not employed as an additive cancer therapy, but as the sole chemotherapeutic agent for patients with therapy-resistant, advanced tumors. The results of the SECAR study are very promising. After two weeks of high-dose sodium selenite, in the majority of patients the previously resistant tumor once again responded to chemotherapy. Moreover, a regression of the tumor was shown for certain types of cancer.

Additional studies are planned and will deliver detailed data on these very promising results.

Topic of study

With the SECAR study, the authors wanted to answer the following questions about the effect of sodium selenite on cancer:

1. Does sodium selenite have a direct anti-tumoral effect?
2. Can sodium selenite reverse chemo-resistance?
3. Can sodium selenite alleviate the toxic effects of chemotherapy?

In order to be able to answer these questions, all patients included in the study were treated with the identical chemotherapy after treatment with sodium selenite. It was therefore possible to compare the toxicity and primary anti-tumoral effect before and after the sodium selenite therapy.
### Profile of adverse drug reactions degree 1-2 for high-dose sodium selenite

<table>
<thead>
<tr>
<th>Reaction</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td></td>
</tr>
<tr>
<td>Cramps in legs/fingers</td>
<td></td>
</tr>
<tr>
<td>Breath with garlic odor</td>
<td></td>
</tr>
<tr>
<td>Anorexia</td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td></td>
</tr>
<tr>
<td>Respiratory distress</td>
<td></td>
</tr>
<tr>
<td>Pain at the infusion point</td>
<td></td>
</tr>
<tr>
<td>Chest pain</td>
<td></td>
</tr>
<tr>
<td>Gastritis</td>
<td></td>
</tr>
<tr>
<td>Stomach pain</td>
<td></td>
</tr>
<tr>
<td>Stomach swelling</td>
<td></td>
</tr>
<tr>
<td>Hot flashes</td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td></td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td></td>
</tr>
<tr>
<td>Itching on the legs</td>
<td></td>
</tr>
<tr>
<td>Thrombopenia</td>
<td></td>
</tr>
</tbody>
</table>

*Fig. 1*
Study design

The SECAR study was an open-label dose-escalating phase I clinical trial with intravenously administered sodium selenite as the single active ingredient.[1] The study included 34 patients with various therapy-resistant tumors. It primarily dealt with lung cancer (71%). The second most common type of tumors were colon cancer (12%).

Groups of three patients were formed for the dose-escalating study. This group received the same dose of sodium selenite during the entire treatment. If the patients showed no dose-limiting toxicity symptoms, then the dose was increased. Dose-limiting toxicity for 0/3 or 1/6 of the patients were defined as maximum tolerated dose.

The primary endpoint of the study was safety, the dose-limiting toxic effects, and the maximum tolerated dose of sodium selenite. A secondary endpoint was the evaluation of the primary response to sodium selenite.

The maximum tolerated dose of sodium selenite: 10.2 mg/m²

Almost no symptoms occurred in doses lower than 3.0 mg/m² selenium. The most common adverse reactions were fatigue, nausea and vomiting (Fig. 1). These side effects occurred starting from doses of 4.5 mg/m². Adverse reactions greater than degree 3 occurred only for doses greater than 12.8 mg/m² (Fig. 2). For a dose ≤ 10.2 mg/m², no dose-limiting toxicity occurred. Dose-limiting toxicities of sodium selenite were acute, of short duration and reversible within 1-2 days. Diverse biological markers of the organ functions showed no critical systemic toxicity. The authors conclude that a dosage of ≤ 10.2 mg/m² selenium per day for 2 weeks is safe and tolerable. For doses of 10.2 mg/m² selenium and above, betamethasone and omeprazole were routinely administered as a pretreatment to counteract the most frequent adverse reactions.

How is the specification mg/m² converted to µg?

The surface (m²) is calculated as follows:

\[ \text{height [cm]} \times \text{weight [kg]} / 3600 \]

An average patient with 170 cm and 70 kg has a surface area of 1.82 m². The maximum tolerable dose of 10.2 mg/m² selenium per day yields a daily dose of 18.56 mg or 18,564 µg. The dose of 3.0 mg/m² selenium, when almost no symptoms appeared, corresponds to a daily dose of 5,460 µg selenium (Fig. 3).

1,000 to 2,000 µg selenium in the form of sodium selenite is therefore safe and generally not associated with adverse reactions.
### Profile of adverse reactions of degree 3 - 4 for high-dose sodium selenite

<table>
<thead>
<tr>
<th>Frequency (%)</th>
<th>Fatigue</th>
<th>Nausea</th>
<th>Pressure on the thorax</th>
<th>Hallucinations</th>
<th>Anxiety</th>
<th>Confusion</th>
<th>Unconsciousness</th>
<th>Respiratory distress</th>
<th>ECG changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Fig. 2**

### Dosage of sodium selenite per day for an average patient (170 cm, 70 kg)

- **18,564 µg selenium**
  - Maximum tolerable toxicity
- **8,190 µg selenium**
  - Appearance of adverse reactions
- **5,460 µg selenium**
  - Few adverse reactions

**Fig. 3**
The plasma selenium concentration was measured on day 1, 5, 8 and 12 of the therapy with sodium selenite, before and after the infusion (Fig. 4). A close correlation was revealed between actual and calculated plasma selenium concentration. The maximum plasma selenium concentration increased linearly with the total selenium dose during the entire study. The median plasma half-life was 18.25 hours.

High-dose sodium selenite stabilized more than a third of the patients with therapy-resistant, advanced tumors

The results regarding the anti-tumoral effect of sodium selenite were very promising, but must be further examined in additional studies due to the low number of patients. Sodium selenite displayed no uniform effect on the tumor size. However, after the sodium selenite treatment, 13 patients (38%) showed a stable disease. 16 patients (47%) were stable after subsequent chemotherapy. In the following six months, one patient showed a gradually improved response to the sodium selenite treatment. Half a year later, the tumor was no longer detectable. The patient is still alive and has been recurrence-free for more than six years.

Stable disease for 38% of the participants after sodium selenite therapy, or for 47% with a subsequent chemotherapy who showed a stable disease, is a significant indication for additional studies with high-dose sodium selenite as monotherapy.

In total, the sodium selenite treatment did not result in a significantly higher overall survival rate. This was primarily because of the small number of patients in the study. However, therapy with high-dose sodium selenite and subsequent chemotherapy also had no negative influence on survival. Two patients are still alive (after five years and one year). The median value of the survival period after sodium selenite treatment was 6.5 months; since the participants in the trial had therapy-resistant advanced tumors, this was a fairly long time.

Sodium selenite reversed chemotherapy resistance

The SECAR study shows that high-dose sodium selenite by itself is able to affect certain tumors. Indeed, this effect can be intensified by subsequent chemotherapy. It is especially interesting to note that many of the patients responded again to their first-line chemotherapy. In these patients, the therapy with high-dose sodium selenite could reverse the previous chemotherapeutic resistance.

In the SECAR study, very high doses of sodium selenite were administered in 20 or 40 minutes. Since sodium selenite has a short half-life period, additional studies should examine whether a steady-state status can be attained with an infusion over a prolonged time period, resulting in an improved clinical effect of sodium selenite and changes in the maximum tolerated dosage.
Plasma selenium concentration for high-dose sodium selenite therapy

Day 1
- before injection
- after injection

Day 5
- before injection
- after injection

Day 8
- before injection
- after injection

Day 12
- before injection
- after injection

Plasma selenium concentration [µg/l]

3 mg/m² selenium
4.5 mg/m² selenium
10.2 mg/m² selenium

3 mg/m² selenium
4.5 mg/m² selenium
10.2 mg/m² selenium

Fig. 4

Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study
Brochures

We will gladly send you our detailed brochure “Selenium as complementary therapy in oncology”.

Order by e-mail: information@biosyn.de
(Key word “brochure / oncology”)

We furthermore offer extensive information on the topics “Selenium in intensive care as an adjunctive therapy for sepsis, ischaemia/reperfusion and reanimation” and “Selenium and the thyroid gland” – for specialists and patients.

Additional information

Order by e-mail: information@biosyn.de

If you have any specific questions on this topic, please call us at: +49 (0) 711-57532-00

Imprint

biosyn Arzneimittel GmbH
Schorndorfer Straße 32
70734 Fellbach, Germany

information@biosyn.de
www.biosyn.de
www.biosyncorp.com

Managing Directors: Dr. Thomas Stiefel and Ortwin Kottwitz
Commercial Register: County Court Stuttgart HRB 262712
Place of performance: Fellbach, Legal Venue Stuttgart

Photo credits: Cover page © Anne Clark / istockphoto